Identification of uridine phosphatase 1 as a potential therapeutic target in gastric cancer by integrated bioinformatics analysis and experimental validation [0.03%]
整合生物信息学分析和实验验证识别尿苷酸磷酸酶1作为胃癌潜在治疗靶点
Yongfeng Wang,Yichen Feng,Chengzhang Zhu et al.
Yongfeng Wang et al.
Gastric cancer remains a major global health challenge, and its early diagnosis and prognosis prediction pose significant challenges to the current clinical treatment of gastric cancer. Finding gastric cancer biomarkers is essential to comp...
Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR-mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors [0.03%]
应用下一代测序技术预测表皮生长因子受体酪氨酸激酶抑制剂治疗的晚期肺腺癌EGFR突变患者的短无进展生存期
Po-Hsin Lee,Yi-Chun Hsiao,Yen-Hsiang Huang et al.
Po-Hsin Lee et al.
For patients with advanced EGFR-mutant lung adenocarcinoma, progression-free survival (PFS) is significantly improved by epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) medications. However, a subset of patients still ...
Patient-derived organoid modeling predicts personalized drug responses in prostate-metastatic mantle cell lymphoma: a case report [0.03%]
患者衍生器官模型预测前列腺转移性套细胞淋巴瘤的个性化药物反应：病例报告
Xiaoting Wang,Gang Fu,Jiayi Wan et al.
Xiaoting Wang et al.
Tumor heterogeneity represents a significant challenge in cancer treatment. Current therapeutic strategies frequently rely on single biopsy assessments that may not fully capture tumor complexity. In this study, we developed prostate patien...
Inhibition of nuclear receptor coactivator 5 overcomes acquired lenvatinib resistance driven by protein kinase B-mammalian target of rapamycin signaling in hepatocellular carcinoma [0.03%]
核受体共激活因子5抑制可克服由蛋白激酶B-哺乳动物雷帕霉素靶点信号诱导的肝细胞癌继发性仑伐替尼耐药问题
Hongyuan Zhou,Qin Zhang,Lu Yang et al.
Hongyuan Zhou et al.
Lenvatinib, a multiple-receptor tyrosine kinase inhibitor, has gained recent approval for its use as a first-line treatment of hepatocellular carcinoma (HCC). While lenvatinib demonstrates notable therapeutic efficacy, the drug resistance u...
E26 transformation-specific transcription factor 3 tips the balance: repressing tropomyosin 2 to fuel Yes-associated protein 1-driven cisplatin resistance in ovarian cancer [0.03%]
E26转化特异性转录因子3打破平衡：通过抑制肌动蛋白2促进YAP1驱动的顺铂耐药性在卵巢癌中的作用
Yan Wang,Zhujing Xu,Chanfeng He et al.
Yan Wang et al.
Cisplatin resistance remains a major challenge in the treatment of ovarian cancer, significantly limiting therapeutic efficacy. This study aimed to investigate the role of E26 transformation-specific transcription factor 3 (ELK3) in cisplat...
Safety and efficacy of ivosidenib in the treatment of isocitrate dehydrogenase 1 mutant cholangiocarcinoma and acute myeloid leukemia: a systematic review and meta-analysis [0.03%]
伊伏西達尼治療異柠檬酸脱氢酶1突变胆管癌和急性髓系白血病安全性和有效性的系统评价和meta分析
Rameez Qasim,Laraib Anmol,Izza Shakeel et al.
Rameez Qasim et al.
Isocitrate dehydrogenase 1 (IDH1) mutations have gained interest because of their association with malignancies, including cholangiocarcinoma and acute myeloid leukemia. Ivosidenib, an inhibitor of IDH1 mutations, inhibits the formation of ...
Effect of valproic acid and levetiracetam administration on the survival of glioma patients: a meta-analysis study [0.03%]
丙戊酸和雷特拉西坦对胶质瘤患者生存率影响的荟萃分析研究
Arya Shirani,Mobin Obeidinia,Makan Ziafati et al.
Arya Shirani et al.
In this meta-analysis study, the effect of valproate (VPA) and levetiracetam (LEV) on the survival of glioma patients taking temozolomide (TMZ) was investigated. The cumulative hazard ratios (HR) of overall survival (OS) and progression-fre...
VTCN1 emerges as a biomarker of immune tolerance in osimertinib-resistant lung cancer [0.03%]
VTCN1成为奥希替尼耐药性肺癌免疫耐受生物标志物的新证据
Lifang Wang,Jingjie Liu,Bin Shi
Lifang Wang
Osimertinib is an effective strategy for nonsmall-cell lung cancer (NSCLC). However, the acquired resistance neutralizes the efficacy of osimertinib. Herein, we investigated the potential biomarkers of osimertinib-resistant lung cancer. GSE...
Overcoming refractory leptomeningeal metastasis in nonsmall cell lung cancer with intrathecal pemetrexed and osimertinib: a case report [0.03%]
贝伐珠单抗联合白蛋白紫杉醇治疗转移性三阴乳腺癌的疗效观察：一例报告及文献复习
Li Xue,Xuhui Zhao,Xiaohui Tai et al.
Li Xue et al.
Leptomeningeal metastasis (LM), a devastating complication of advanced nonsmall cell lung cancer (NSCLC), severely compromises patient survival and quality of life. Currently, standardized diagnostic criteria and treatment protocols for NSC...
Distribution of side effects of anti-EGFR treatments in patients with metastatic colorectal cancer and evaluation of their relationship with survival [0.03%]
抗EGFR治疗转移性结直肠癌患者的不良反应分布及与生存期的关系评估
Mert Erciyestepe,Okan Aydin,Sermin Dinc Sonusen et al.
Mert Erciyestepe et al.
Many previous studies have investigated cetuximab and panitumumab's efficacy, safety, and side effects. Only a few studies have evaluated the relationship between toxicity and survival. Therefore, we conducted this study to examine the rela...